Allergy

asthma & allergy friendly® Certification Program Honors Clients for Commitment to Innovation

Retrieved on: 
Wednesday, March 6, 2024

WASHINGTON, March 6, 2024 /PRNewswire-PRWeb/ -- The asthma & allergy friendly® Certification Program has recognized the dedication and innovation of several of the Program's clients and called attention to products that help consumers create healthier indoor environments. The asthma & allergy friendly® Certification Program is a collaborative initiative between Allergy Standards Limited (ASL) and the Asthma and Allergy Foundation of America (AAFA) that helps consumers identify products more suitable for people with asthma and allergies.

Key Points: 
  • The asthma & allergy friendly® Certification Program, which helps consumers identify products more suitable for people with asthma and allergies, has recognized the dedication and innovation of several of the Program's CERTIFIED clients.
  • WASHINGTON, March 6, 2024 /PRNewswire-PRWeb/ -- The asthma & allergy friendly® Certification Program has recognized the dedication and innovation of several of the Program's clients and called attention to products that help consumers create healthier indoor environments.
  • The asthma & allergy friendly® Certification Program is a collaborative initiative between Allergy Standards Limited (ASL) and the Asthma and Allergy Foundation of America (AAFA) that helps consumers identify products more suitable for people with asthma and allergies.
  • The Healthy Homes exhibit highlighted how consumers can manage asthma and allergy triggers through a whole-home approach, including using the asthma & allergy friendly® Certification Mark as a trusted signpost.

Allegra Airways Introduces Revolutionary Nationwide Mapping Tool Providing Outdoor Enthusiasts with Real-Time Routes with Less Pollen and Less Air Pollution

Retrieved on: 
Tuesday, March 5, 2024

NEW YORK, March 5, 2024 /PRNewswire/ -- Allegra, a leading brand in allergy relief, announced today the nationwide launch of Allegra Airways, a groundbreaking navigation tool designed to help outdoor enthusiasts find real-time walking, biking, and running routes with cleaner air based on hyperlocal pollen and air pollution levels on a street-by-street basis. Recent studies show that air pollution alters the pollen structure, releasing more allergens and making pollen more "aggressive." 1,2 These allergens can likely penetrate deeper into your airways, provoking more severe allergy symptoms1,2. What's more concerning is that seasonal allergy symptoms are on the rise, with an estimated 50% of the global population expected to have an allergic disease by 2050.3

Key Points: 
  • Recent studies show that air pollution alters the pollen structure, releasing more allergens and making pollen more "aggressive."
  • "By harnessing hyperlocal data on pollen and air pollution levels, Allegra Airways guides people along cleaner routes, making an invisible problem visible and enabling people to pursue their passions outdoors with confidence."
  • Allegra Airways will debut at SXSW, a global event that sits at the intersection of innovation and culture.
  • Join the Allegra Airways community to learn more about how air pollution impacts pollen and how Allegra Airways can help you breathe easy.

Mosquito Squad Introduces Four New Pest Control Packages Expertly Tailored to Region-Specific Pest Issues

Retrieved on: 
Tuesday, March 5, 2024

To deliver effective pest control services within its local territories, Mosquito Squad has tailored each package to help protect against the pests prevalent in those specific markets.

Key Points: 
  • To deliver effective pest control services within its local territories, Mosquito Squad has tailored each package to help protect against the pests prevalent in those specific markets.
  • Recognizing the diversity of pest challenges, Mosquito Squad acknowledges that a singular solution doesn't suffice; therefore, Mosquito Squad's highly trained technicians are able to develop the most appropriate package for region-specific pest issues.
  • Mosquito Squad continues to highlight the importance of pest management to help control diseases transmitted by pests.
  • In addition to Pest Packages, Mosquito Squad continues to offer homeowners year-round mosquito and tick protection through its Mosquito Control Barrier Protection System, helping keep these pests at bay for up to three weeks after application.

JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval

Retrieved on: 
Tuesday, March 5, 2024

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.1 JUVÉDERM® VOLUMA® XC is the first and only hyaluronic acid (HA) dermal filler to receive U.S. FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.*1

Key Points: 
  • *1
    "The approval of JUVÉDERM® VOLUMA® XC to treat temple hollows further demonstrates Allergan Aesthetics commitment to innovation and addressing patient needs," said Carrie Strom, President, Allergan Aesthetics and Senior Vice President, AbbVie.
  • "This is the first U.S. FDA approval of a hyaluronic acid dermal filler for use in the upper face and addresses a real unmet need for patients."
  • The safety of JUVÉDERM® VOLUMA® XC in patients with a history of excessive scarring or pigmentation disorders has not been studied.
  • To report a side effect with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1‑877‑345‑5372.

Hugel Receives FDA Approval in the United States of Letybo (letibotulinumtoxinA-wlbg) for Injection for the Treatment of Glabellar Lines

Retrieved on: 
Monday, March 4, 2024

NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults. In the coming months, Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the back half of 2024.

Key Points: 
  • NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults.
  • This is a huge achievement for Hugel as we focus on becoming a top aesthetics brand in the U.S.," stated James Hartman, President, Hugel America.
  • Joely Kaufman, MD, commented, "The results from the clinical trials for letibotulinumtoxinA demonstrate efficacy, and a convincing safety profile in the treatment of glabellar lines1.
  • FDA approval is supported by positive results from three completed phase III trials that enrolled more than 1,000 subjects in the U.S. and Europe1.

Ionis announces new chief global product strategy officer to lead next phase of commercial growth

Retrieved on: 
Thursday, February 29, 2024

CARLSBAD, Calif., Feb. 29, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Kyle Jenne has rejoined Ionis as executive vice president, chief global product strategy officer, to lead all aspects of commercialization at the Company. Mr. Jenne has more than 25 years of biopharmaceutical commercial and executive leadership experience and has launched innovative medicines across a broad range of therapeutic areas including cardiovascular, neurology and allergy.

Key Points: 
  • Onaiza Cadoret-Manier, chief global product strategy and operations officer, is leaving the company to pursue another opportunity.
  • She has built a stellar team of professionals with deep experience across all aspects of commercialization," said Brett P. Monia, Ionis' chief executive officer.
  • Mr. Jenne previously spent five years in commercial leadership roles at Ionis and Akcea, which was fully acquired by Ionis in 2020.
  • His most recent role at Ionis was as EVP & chief commercial officer.

On Feb 6th, Penn Medicine Becker ENT & Allergy Opens a New Location to Increase Access to Quality Care in Woodbury, NJ

Retrieved on: 
Wednesday, February 28, 2024

WOODBURY, N.J., Feb. 28, 2024 /PRNewswire-PRWeb/ -- Expanding Patient Care: Penn Medicine Becker ENT & Allergy's New Woodbury Facility

Key Points: 
  • WOODBURY, N.J., Feb. 28, 2024 /PRNewswire-PRWeb/ -- Expanding Patient Care: Penn Medicine Becker ENT & Allergy's New Woodbury Facility
    The new Penn Medicine Becker ENT & Allergy location in Woodbury is part of their ongoing mission to deliver comprehensive care for ear, nose, throat, and allergy issues to more patients.
  • What the New Penn Medicine Becker ENT & Allergy Location Means for Woodbury, NJ
    The opening of the new Becker ENT location in Woodbury is a major boon for the local community.
  • Penn Medicine Becker ENT & Allergy offers a vast array of ENT and allergy services .
  • Contacting Penn Medicine Becker ENT & Allergy for Care in Woodbury, NJ
    To experience the quality and personalized care that Penn Medicine Becker ENT & Allergy offers, residents of Woodbury, NJ, and surrounding areas can schedule an appointment.

Enhancing Your Lips: Lip Flips vs. Lip Fillers

Retrieved on: 
Tuesday, February 27, 2024

When deciding between lip flips and lip filler, it's essential to consider your aesthetic goals, budget, and comfort level with each procedure.

Key Points: 
  • When deciding between lip flips and lip filler, it's essential to consider your aesthetic goals, budget, and comfort level with each procedure.
  • Let's dispel some of the most common misconceptions about lip flips and lip fillers.
  • Typically, the effects of lip fillers endure for around six months to one year, while lip flips generally last between 6 to 8 weeks.
  • Some people think that lip flips and lip fillers can cause long-term damage or change the structure of the lips.

Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024

Retrieved on: 
Sunday, February 25, 2024

The presentation of the poster titled "A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis" by Longbio Pharma marked a significant moment during the conference.

Key Points: 
  • The presentation of the poster titled "A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis" by Longbio Pharma marked a significant moment during the conference.
  • This Phase II study shows that 100mg LP-003 significantly improved nasal symptoms (TNSS score) of uncontrolled seasonal allergic rhinitis patients despite SoC treatment.
  • We are honored to unveiled the exciting Phase II results of LP-003, the first registrational clinical trial of anti-IgE antibody for AR conducted in China."
  • As Longbio Pharma charts its course forward, the successful Phase II study of LP-003 in allergic rhinitis represents a pivotal milestone in advancing the treatment landscape for allergic diseases.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

Retrieved on: 
Wednesday, February 21, 2024

IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs. BOTOX® Cosmetic partnered with IFundWomen to launch the program in 2023, and in the second year, will award a new group of 20 women entrepreneurs each with $25,000 grants to fund and grow their businesses. Additionally, BOTOX® Cosmetic continues to support these businesses through mentorship, coaching, crowdfunding, and community.

Key Points: 
  • FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY
    IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs.
  • We are grateful to learn from them and thrilled to continue this program into a second year with a new cohort of extraordinary women entrepreneurs."
  • I am forever grateful to this program for connecting me to a group of women entrepreneurs who together are helping to bridge the Confidence Gap.
  • Starting today, women entrepreneurs across the country can apply for the BOTOX® Cosmetic x IFundWomen grant at www.botoxcosmetic.com/realimpact for the chance to be one of 20 recipients.